Acquisition of Antibody Specialist Teneobio for US$2.5 B by Amgen
By Ashish Tripathi
Pharma Deals Review: Vol 2021 Issue 10 (Table of Contents)
Published: 18 Oct-2021
DOI: 10.3833/pdr.v2021.i10.2639 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its pipeline, Amgen has agreed to acquire Teneobio to discover, develop and commercialise new molecules for the treatment of wide range of diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS